Efthymios Manolis

Implementation of proteomic biomarkers: making it work

Harald Mischak, John P. A. Ioannidis, Àngel Argilés et al. · European Journal of Clinical Investigation · 2012 · 169 citations · Full text

Pharmacy, Biomedical Sciences, Biostatistics +17

Scientific and regulatory evaluation of mechanistic <i>in silico</i> drug and disease models in drug development: Building model credibility

Flora T. Musuamba, Ine Skottheim Rusten, R Lesage et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 142 citations · Full text

Pharmacy, Risk Management, Method Validation +11

Proposals for model‐based paediatric medicinal development within the current European Union regulatory framework

Efthymios Manolis, Gérard Pons · British Journal of Clinical Pharmacology · 2009 · 124 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives

Scott Marshall, Rajanikanth Madabushi, Efthymios Manolis et al. · CPT Pharmacometrics & Systems Pharmacology · 2018 · 123 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +11

Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function

Nassim Kamar, Étienne Chatelut, Efthymios Manolis et al. · American Journal of Kidney Diseases · 2004 · 82 citations

Pharmacy, Pharmacokinetics, Pharmacology +16